BackgroundThe search for novel non-invasive biomarkers such as epigenetic molecular markers is new hope for common & burdensome cancers. We aim to assess serum expression of miRNA 27a and miRNA150-5p in endometrial cancer patients. MethodsSerum was drawn for 36 un-intervened endometrial cancer patients scheduled for hysterectomy & 35 controls. miRNA 27a and miRNA150-5p were measured by real time reverse transcription polymerase chain reaction. ResultsSigni cant overexpression of both miRNA in patients (p < 0.001). At cutoffs 0.2872 & 1.02, miRNA 27a showed 100%sensitivity, speci city, positive & negative predictive values. miRNA150-5p showed 88.89%sensitivity, 100%speci city, 100%positive and 78.9%negative predictive values. Areas under curve were 1.0 for miRNA 27a, 0.982 for miRNA 150 performing much better than Ca125. miRNA 27a was signi cantly associated with type I endometroid endometrial cancer. ConclusionWe suggest miRNA 27a and miRNA-150-5P as promising biomarkers of endometrial cancer possibly part of a miRNA panel for management.

Cholangiocarcinoma (CCA) is a rare tumor comprising approximately 3% of gastrointestinal tumors with an overall incidence of less than 2/100 000. It is the second most common primary hepatic malignancy following hepatocellular carcinoma (HCC). 1,2 CCA incidence has been increasing globally during the last decades, where its incidence increases with age. 3 According to the anatomic location, CCA is classified into intrahepatic (IH-CCA) and extrahepatic (EH-CCA) where the later accounts for 80%-90% of all cases. 4 The commonest risk factors for CCA are primary sclerosing cholangitis (PSC), 5 chronic liver disease (including chronic viral hepatitis B and C), 6 and intrahepatic stones (hepatolithiasis). 7 CCA patients remain clinically silent until the advanced stages of the disease. The common clinical feature of EH-CCA is biliary obstruction resulting in painless jaundice, while IH-CCA presents in most cases

No abstract

Lipotoxicity is defined as deposition of excess fat associated with an inflammatory response. Metabolomic analysis of fatty acids (FAs) can be a marker of silent inflammation. ω3‐Enriched diet, celecoxib, and safranal may have a protective anti‐inflammatory role. In this work, total FAs extracted from red blood cells and arachidonic acid‐to‐eicosapentaenoic acid (AA‐to‐EPA) ratios were assessed using GC–MS assay in single‐ion monitoring mode. The study was conducted on 64 male rats divided into eight groups: I, controls; II, rats received high‐fat diet (HFD), III, rats received ω‐6‐enriched HFD; IV, rats received ω‐3‐enriched HFD; V, rats received celecoxib with HFD; VI, rats received safranal with HFD; VII and VIII, rats received celecoxib and safranal with ω‐3 HFD, respectively. GC–MS Gas chromatography Mass spectrometry was performed for analysis of fatty acid methyl ester. Enzyme‐linked immunosorbent assay was used to analyze serum interleukin‐6 (IL‐6) and transforming growth factor‐beta 1 (TGF‐β1) concentrations. A statistically significant decrease of AA‐to‐EPA ratio was observed in group VII when compared with the groups receiving HFDs. This group also showed the lowest serum IL‐6 level and highest TGF‐β1 level. In conclusion, ω3‐enriched diet along with drugs (e.g. celecoxib) and herbal medications (e.g. safranal) may have an anti‐inflammatory effect in lipotoxicity. GC–MS with single‐ion monitoring is valid for the analysis of FAs.

Objectives Anti-carbamylated protein antibodies (anti-CarP Abs) are present in patients with RA, however, their association with bone loss is not confirmed. The purpose of this study was to determine the relation between the serum level of anti-CarP Abs in premenopausal RA women and disease activity and bone loss. Methods This case–control study was conducted on 48 premenopausal women with RA and 48 matched healthy premenopausal women. All RA women were subjected to clinical examination, disease activity assessment using the 28-joint DAS (DAS28) and Clinical Disease Activity Index (CDAI), functional assessment using the HAQ, physical activity assessment using the International Physical Activity Questionnaire (IPAQ), fatigue assessment using the Modified Fatigue Impact Scale (MFIS), serological tests as well as anti-CarP Abs using ELISA. Moreover, the BMD was measured by DXA and plain X-ray of both hands was done to assess juxta-articular osteopenia and erosions. Results The anti-CarP Abs level was significantly higher in RA patients than in healthy controls. The serum level of anti-CarP Abs had a significant positive correlation with the RA DAS28, CDAI, HAQ, MFIS and original Sharp score, while a significant negative correlation was present with the IPAQ. Anti-CarP Abs were negatively correlated with either spine BMD or Z-score and positively correlated with the original Sharp score. Conclusion Anti-CarP Abs were higher in premenopausal RA women compared with older and BMI matched healthy women. Anti-CarP Abs are associated with higher RA disease activity, increased disability and fatigability and decreased physical activity. Moreover, anti-CarP Abs are associated with systemic trabecular bone loss as well as local bone loss.

The pathophysiology of varicocele remains to be unknown. Several genetic factors have been implicated in varicocele etiopathogenesis. We studied the relationship between NOS3 c.894G>T, c.786T>C and 4b/a polymorphisms to varicocele risk and their prognostic value as regards improvement of the post‐operative seminal parameters &/or seminal malonaldehyde levels. The three NOS3 polymorphisms were evaluated in 100 patients with varicocele and 100 healthy subjects by RT‐PCR. Seminal plasma MDA level was measured pre‐operatively and 3 months after varicocelectomy by the thiobarbituric acid method. The GT, TT, TC and bb genotypes of NOS3 polymorphism were more commonly observed in varicocele patients (30%, 9%, 28% and 70% respectively) compared to normal controls (12%, 0%, 10% and 50% respectively). The mean percentage of post‐varicocelectomy seminal MDA reduction was highest with the GT genotype (p < .001). Genotypes GT+TT, TC and bb were associated with varicocele occurrence in our patients. The T (c.894G>T), C (c.786T>C) and b (NOS3 intron 4 VNTR) alleles were significantly associated with varicocele occurrence in our cohort of patients. We also report a better response regarding the reduction of seminal MDA after varicocelectomy with the GT and ba genotypes.

Diabetic dyslipidemia is a significant contributor in the pathogenesis of type 2 diabetes (T2D). The study aimed at comparing the effect of dapagliflozin, liraglutide, and atorvastatin alone or their combinations on lipids and inflammatory markers and their vascular impact in T2D rats. There were 56 male albino rats included in the study and divided into two main groups. Group A (8 rats) served as normal control. Group B (48 rats) were streptozotocin-nicotinamide-induced diabetic rats. Subgroups (B-1, B-2, B-3, B-4, B-5, and B-6) received (no medications, dapagliflozin, liraglutide, atorvastatin, dapagliflozin + atorvastatin, and liraglutide + atorvastatin), respectively. Urine albumin/creatinine ratio (UACR), glycosylated hemoglobin (HBA1c), fasting serum glucose (FSG), serum low-density lipoproteincholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), TGs, lipoprotein(a) Lp (a), serum thyrotropin (TSH), highly sensitive C-reactive protein (hs-CRP) and advanced glycation end products (AGEs), were assessed. Qualitative and quantitative histological examination of kidneys focused on renal corpuscles. Dapagliflozin improved the studied parameters but with statistically insignificant increase in LDL-C, Lp (a) and significant increase in UACR. Atorvastatin improved the studied parameters but with statistically insignificant increase in FSG and HbA1C. Liraglutide and the combination groups significantly improved all studied parameters. Histologically, liraglutide and atorvastatin produced therapeutic effect, while dapagliflozin depicted nephrotoxic effect. Combination groups resulted in better effects with normalization of most of renal corpuscles. There were positive correlations between LDL-C and hs-CRP, AGEs, TSH and mesangial expansion. Combination of atorvastatin with liraglutide can improve its vasculoprotective effect. Moreover, combination of atorvastatin with dapagliflozin can ameliorate its possible nephrotoxic effect.

Several risk factors are participating in the development of RCC including age, sex, socioeconomic status, genetic predisposition, cigarette smoking, obesity, hypertension and alcohol intake (Kabaria et al., 2016).